CME Snack

Facilitating Definitive Diagnosis: Identification and Measurement of AD Pathophysiology

Launch Date
08/18/2023
Credit Amount
0.75
Credit Expires
08/18/2024
This activity is part of a series

Faculty

Eric G. Tangalos, MD, FACP, AGSF, CMD
Professor of Medicine
Division of Primary Care Internal Medicine, Geriatrics and Palliative Care
Mayo Clinic
Rochester, MN
Eric G. Tangalos, MD, FACP, AGSF, CMD

Dr. Eric Tangalos is Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He served as Chair of Primary Care Internal Medicine from 1997 to 2006. Dr. Tangalos received his undergraduate training from the University of Michigan, is a graduate of the Loyola University Stritch School of Medicine in Chicago, and was a resident and fellow in Internal Medicine at Mayo.

He is a past president of AMDA, The Society for Post-Acute and Long-Term Care Medicine, and is a fellow and past governor of the American College of Physicians. He is a past director of the American Geriatrics Society and serves on their Foundation for Health in Aging. Dr. Tangalos served 8 years on the national board of the Alzheimer’s Association and was a member of their executive committee. He also served as Chair of the Omnicare P&T Committee for 20 years.

Dr. Tangalos was Medical Director at the Samaritan Bethany nursing home from 1981 until his retirement from Mayo in 2019.  His certification as a medical director is current and will be approved again by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) in June 2022.  He is currently recredentialed by Mayo for continuing service both to the Rochester campus and the Health Care System in Minnesota.  Over the past 3 years he has worked face-to-face with patients in Austin and has provided in-basket coverage to Austin, Albert Lea, Faribault, and Owatonna.

Dr. Tangalos has been an investigator with the Mayo Clinic Alzheimer’s Disease Research Center since 1987 and is currently active with the Alzheimer’s Association as course director for a Project ECHO seminar series. Additionally, Dr. Tangalos continues to review NIH SBIR/STTR grant applications while working as a founding member of the American Telemedicine Association.

Henrik Zetterberg, MD, PhD
Professor of Neurochemistry
Head of the Department of Psychiatry and Neurochemistry
University of Gothenburg
Clinical Chemist, Sahlgrenska University Hospital
Gothenburg, Sweden
Henrik Zetterberg, MD, PhD

Henrik Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and a clinical chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a key member of the Hong Kong Center for Neurodegenerative Diseases and Visiting Professor in the University of Wisconsin (UW) Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin. His main research focus and clinical interest are in fluid biomarkers for brain diseases, neurodegenerative diseases in particular. He has published more than 2,000 scientific articles and received many awards.

Explore By Section
Statement of Need Learning Objective Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Rapidly advancing biomarker research is adding much-needed clarity to the differential diagnosis of Alzheimer’s disease (AD), particularly in early disease, but there are delays in the detection and diagnosis of AD. To combat these delays and allow patients access to early interventions that may slow disease progression, it is imperative that health care professionals involved in AD/dementia care are aware of advances in AD diagnostics and are able to translate these advances in the real-world practice setting.

In this CME Outfitters Snack, expert faculty will discuss biomarker research findings presented at the Alzheimer’s Association International Conference (AAIC), review the identification and measurement of AD pathophysiology, examine a framework for evidencing biomarker profiles of AD, provide updates on prognostic performance and interpretation of biomarkers, and conduct a case-based discussion of clinical impacts and applications.

Learning Objective

Interpret biomarker-based investigations to identify patients with AD pathology in clinical and research settings.

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

Dementia specialists, neurologists, psychiatrists, neurology and psychiatry nurse practitioners (NPs), physician associates (PAs), and other clinicians caring for patients with AD in the United States and globally (with the exception of UK-based clinicians.)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.75

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.75

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC 0.75

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

PAs (AAPA) 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hour. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Tangalos reports the following financial relationships:

Advisory Board: Acadia Pharmaceuticals Inc.; Biogen; and Eisai Inc.

Consultant: Cyclo Therapeutics, Inc. (DSMB); Genentech, Inc.; Prothena (DSMB); and Roche

Stock Shareholder (ownership interest): AbbVie Inc.; Johnson & Johnson; and Pfizer Inc.

Dr. Zetterberg reports the following financial relationships:

Advisory Board/Consultant: AbbVie Inc.; Acumen Pharmaceuticals, Inc.; Alector, Inc.; Alzinova; ALZPath Inc.; Annexon Biosciences; Apellis Pharmaceuticals; Artery Therapeutics, Inc.; AZTherapies, Inc.; Cognito Therapeutics; Cognition Therapeutics; Denali Therapeutics; Eisai Europe Ltd; NervGen Pharma Corp.; Novo Nordisk; OptoCeutics; Passage Bio; Pinteon Therapeutics; Prothena; and Red Abbey

Speakers Bureau: AlzeCure Pharma; Biogen; and Cellectricon; Fujirebio; and Roche

Stock Shareholder (ownership interest): Co-founder and stock shareholder of Brain Biomarker Solutions in Gotheburg AB (BBS), which is a part of the GU Ventures Incubator Program

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Joshua Caballero, PharmD, BCPP, FCCP (peer reviewer)
  • Susan Perry (planning committee)
  • Kellie Busby, PharmD, BCPP (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-206-081823-11

Facilitating Definitive Diagnosis: Identification and Measurement of AD Pathophysiology
Event Date: 08/18/2023
Register

Activities in the Series

Alzheimer’s Disease
08/18/2023

Facilitating Definitive Diagnosis: Identification and Measurement of AD Pathophysiology

0.75
Register Learn More
Alzheimer’s Disease
08/09/2023

Exploring New and Emerging ATTs to Inform Patient Selection and Increase Optimal Care in a Timely Manner

0.75
Register Learn More